5 de abril de 2012

Artigo recomendado: Efficacy and safety of activated recombinant factor VII in cardiac surgical patients

Jean-François Hardy, Sylvain Bélisle and Philippe Van der Linden

Current Opinion in Anaesthesiology 2009,22:95–99

Purpose of review
Excessive bleeding is a common and morbid problem after cardiac surgery. There is no doubt a need for an effective and safe hemostatic agent in order to minimize transfusions and avoid surgical reintervention for hemostasis. Recombinant activated factor VII (rFVIIa) is being used (off-label) increasingly after cardiac surgery to prevent or to control hemorrhage, but its efficacy and safety remain unclear.

Recent findings
Several case reports, case series and registries would tend to support the use of activated recombinant factor VII to control excessive bleeding after cardiac operations. On the contrary, two randomized controlled trials have produced negative results whereas a third has not been published yet. Adverse thrombotic events are reported with increasing frequency.

Summary
At present, the generalized use of rFVIIa to prevent or to control excessive bleeding after cardiac surgery cannot be recommended. The decision to administer a potent hemostatic such as rFVIIa outside its recognized prescribing indications should be made with caution by well informed physicians and discussed with the patient. Patients should be informed about knowledge gaps and pertinent risks, which are both important in the case of rFVIIa.

Caso queira, deixe seu e-mail nos comentários abaixo desta postagem ou solicite pelo e-mail anestesiasegura@sma.com.br e lhe enviaremos o artigo completo.

2 comentários:

Tiago Bandeira disse...

tiagobandeira@hotmail.com

Obrigado

Tiago Bandeira disse...

tiagobandeira@hotmail.com

Obrigado

Pesquisar neste blog

Ocorreu um erro neste gadget